Nervius (Pramipexole Dihydrochloride Monohydrate)

Pramipexole dihydrochloride monohydrate, the active ingredient in Nervius, is a dopamine agonist presented as an oral tablet for systemic use. It targets central nervous system dopamine receptors to alleviate motor symptoms of Parkinson's disease and to diminish the urge to move the legs in restless legs syndrome, providing symptomatic relief for patients.

GNH USA supplies Nervius as a licensed, Good Distribution Practice‑compliant pharmaceutical product to hospitals, pharmacies and clinics worldwide, ensuring quality assurance, traceability and regulatory conformity across international markets and reliable delivery.

Pramipexole acts as a dopamine agonist used in movement‑disorder therapy. - Parkinson's disease: Improves motor control and reduces rigidity and bradykinesia. - Restless legs syndrome: Decreases the urge to move legs and alleviates uncomfortable sensations.

Pramipexole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild stomach upset. - Dizziness: light‑headedness or imbalance. - Somnolence: increased sleepiness. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Hallucinations: visual or auditory disturbances. - Impulse control disorders: compulsive behaviors such as gambling or shopping. - Sudden onset of sleep: unexpected episodes of falling asleep.

When prescribing pramipexole, clinicians should consider several precautionary measures to ensure patient safety. - Renal impairment: dose may need adjustment in patients with reduced kidney function. - Cardiovascular disease: monitor for orthostatic hypotension and arrhythmias. - Psychiatric history: observe for worsening hallucinations or impulse control issues. - Elderly patients: start with low dose and titrate slowly due to increased sensitivity. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Pramipexole can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol, risperidone): may antagonize dopamine agonist effect. - MAO‑B inhibitors (e.g., selegiline): increase risk of hypertensive crisis.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., alcohol, benzodiazepines): may enhance somnolence. - Antihypertensive agents: additive effect on blood pressure. - Serotonergic drugs (e.g., SSRIs): possible increase in serotonin syndrome risk.